News coverage about Zimmer Biomet (NYSE:ZBH) has trended positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet earned a news sentiment score of 0.30 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.122009223022 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Zimmer Biomet Announces FDA Clearance of the Sidus Stem-Free Shoulder System (newkerala.com)
- Keep Eye on 52-week Low Price – Zimmer Biomet Holdings, Inc. (ZBH) – The Stocks News (press release) (thestocksnews.com)
- Hot Tickers: Zimmer Biomet Holdings, Inc. (ZBH), Crocs, Inc. (CROX) – Market Movers (financialqz.com)
- Equities Analysts Offer Predictions for Zimmer Biomet Holdings Inc’s FY2017 Earnings (ZBH) (americanbankingnews.com)
- FDA Nod for Zimmer Biomet’s Sidus, Aids Arthroplasty Arm (zacks.com)
Zimmer Biomet (NYSE:ZBH) opened at $122.10 on Friday. Zimmer Biomet has a 12 month low of $108.03 and a 12 month high of $133.49. The stock has a market capitalization of $24,760.44, a P/E ratio of 15.15, a P/E/G ratio of 1.90 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.79 earnings per share. analysts expect that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Stockholders of record on Friday, December 29th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio is currently 30.19%.
ZBH has been the subject of several research reports. Royal Bank of Canada dropped their price target on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Monday, November 6th. BMO Capital Markets lowered their price target on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Jefferies Group reiterated a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, Canaccord Genuity reiterated a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $137.42.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/01/13/zimmer-biomet-zbh-receives-daily-media-impact-rating-of-0-30.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.